Skip to main content

Table 3 Model fit statistics

From: Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis

Year Fixed effects Random effects
Reference case: RCTs with 100% HER2+ patients and HER2+ subgroups
2008 DIC = 1.69
TotResDev = 2.99 vs. 4
DIC = 3.19
TotResDev = 3.74 vs. 4
Heterogeneity SD (95% CI) = 0.68 (0.01 to 4.55)
2010 DIC = 17
TotResDev = 10.63 vs. 10
DIC = 17.96
TotResDev = 9.66 vs. 10
Heterogeneity SD (95% CI) = 0.37 (0.02 to 2.41)
2012 DIC = 28.67
TotResDev = 19.63 vs. 16
DIC = 26.29
TotResDev = 14.64 vs. 16
Heterogeneity SD (95% CI) = 0.31 (0.05 to 1.16)
2014 DIC = 25.24
TotResDev = 25.67 vs. 25
DIC = 25.76
TotResDev = 23.27 vs. 25
Heterogeneity SD (95% CI) = 0.12 (0.01 to 0.43)
2016 DIC = 28.17
TotResDev = 33.94 vs. 34
DIC = 28.17
TotResDev = 32.07 vs. 34
Heterogeneity SD (95% CI) = 0.08 (0.01 to 0.27)
  1. CI confidence interval, DIC deviance information criterion, HER2+ human epidermal growth factor receptor 2-positive, RCT randomized controlled trial, SD standard deviation, TotResDev total residual deviance